Papworth Hospital is aiming to build on its recent success in recruiting the first patient to ‘PulMiCC’, a new, national, multi-centre clinical trial by inviting further patients to join the trial. The research, funded by Cancer Research UK, aims to examine the benefits of treatment for patients who, after successful treatment for bowel cancer, go on to develop cancer in their lungs.
Papworth is one of 20 leading UK thoracic surgery centres involved in the trial which is being coordinated by the Royal Brompton and Harefield Clinical Trials Unit.
PulMiCC aims to compare the benefits of a type of surgery called metastasectomy against no surgery. Some patients who have been treated for bowel cancer go on to develop pulmonary metastases (cancerous growths) in their lungs. Patients who are fit enough for surgery may be offered a metastasectomy to remove the growths. However, it is not clear whether patients undergoing metastasectomy live longer and have better quality of life than patients who do not undergo the surgery.
Principal investigator for PulMiCC at Papworth Hospital, Thoracic Surgeon, Mr Aman Coonar explains: “We are contacting specialists in colorectal cancer and chest physicians around the region to request that patients who fit the criteria are given the opportunity to join the trial to help answer this key question.”
The Chief Investigator for PulMiCC, Professor Tom Treasure commented “I am delighted that Papworth Hospital has got PulMiCC underway by recruiting the first patient. This is an important step in establishing the feasibility of the trial and we look forward to collaborating with Papworth on this important study.”
Papworth Hospital is a major centre for thoracic surgery and gives the highest priority to research and scientific innovation. The Hospital offers a wide range of diagnostic and treatment procedures including surgery for lung cancer, mesothelioma and sarcoma.